KEVIN G. SHANKS

AIT Laboratories

Indianapolis, IN 46241

(317) 313 - 7911

ab22jr@r.postjobfree.com

ab22jr@r.postjobfree.com

EDUCATION AND CERTIFICATION

July 2012

American Board of Forensic Toxicology

Forensic Toxicology Specialist (FTS)

License 5112

April 2011

Master of Science, Forensic Toxicology

University of Florida, Gainesville, FL

May 2003

Bachelor of Arts, Biology

Franklin College, Franklin, IN

PROFESSIONAL EXPERIENCE

American Institute of Toxicology (AIT Laboratories), Indianapolis, Indiana

Forensic Toxicologist 05/2011 - Present

Assistant Technical Director, Research and Development / Technical Services 04/2010 - 05/2011

Department Manager, Mass Spectrometry Screening / Trace Analysis 03/2009 - 04/2010

Department Manager, Forensics Department 05/2008 - 03/2009

Senior Chemist, Research and Development 05/2005 - 05/2008

Analytical Chemist, Research and Development 05/2003 - 05/2005

Forensic Toxicologist

o Forensic case review, release, client consultation and results interpretation

o Expert witness testimony in human performance and postmortem toxicology

- Admitted as expert in toxicology in Illinois, Indiana, Kentucky, Michigan, Ohio, and Wisconsin

o Consultation regarding designer drugs and other topics in toxicology

o Provide education and training regarding designer drugs and other topics in toxicology

o Research on designer drugs in nonbiological specimens

o Development and validation of methods for the detection of synthetic cannabinoids, synthetic stimulants, and

other designer drugs in postmortem and human performance toxicology specimens (blood, tissue, urine)

o Chemical analysis of nonbiological specimens such as drug paraphernalia and alleged drug substances and

unknown fluids, pills, powders, syringes, and tablets

Assistant Technical Director, Research and Development / Technical Services

o LC/ToF and LC/MS/MS technical support

o Chemical analysis of nonbiological specimens such as drug paraphernalia and alleged drug substances and

unknown fluids, pills, powders, syringes, and tablets

o Developed and validated analytical methods for routine analytes

o Evaluated new software and new technology for implementation in the production laboratory.

o Research on designer drugs in nonbiological and biological specimens

Department Manager, Mass Spectrometry Screening / Trace Analysis

o Daily management duties and leadership of a group of 7 forensic chemists in the routine screening of

postmortem blood, tissue, and urine specimens for drugs of abuse and therapeutic drugs by UPLC/ToF.

- Decreased turnaround time from receipt of a batch to certification from 40 hours to 17 hours

o Chemical analysis of nonbiological specimens such as drug paraphernalia and alleged drug substances and

unknown fluids, pills, powders, syringes, and tablets

o Developed and validated analytical methods for esoteric analytes

Department Manager, Forensics Department

o Daily management duties and leadership of a group of 12 forensic chemists in the routine toxicological

analyses of postmortem blood, tissue, and urine specimens.

o Chemical analysis of nonbiological specimens such as drug paraphernalia and alleged drug substances and

unknown fluids, pills, powders, syringes, and tablets

o Developed and validated analytical methods for esoteric analytes

Senior Chemist, Research and Development

o LC/ToF and LC/MS/MS technical support

o Method development and validation of small molecule drugs in postmortem matrices

o Chemical analysis of nonbiological specimens such as drug paraphernalia and alleged drug substances and

unknown fluids, pills, powders, syringes, and tablets

Analytical Chemist, Research and Development

o Analysis of active pharmaceutical ingredients in a tablet matrix and pharmaceutical solution by following

GMP and GLP protocols

o Duties included organic extraction of active ingredient, sample preparation, instrument setup, instrument

maintenance, and data analysis

Professional Affiliations

Midwest Association for Toxicology and Therapeutic Drug Monitoring (MATT) – Member 2013 – Present

Advisory Committee for the Evaluation of Controlled Substance Analogs (Co-Chair) 2012 – Present

Toxicology and Pharmacology subcommittee (Chair)

Society of Forensic Toxicologists (SOFT) – Full Member 2008 – Present

Publications

Peer Reviewed

“Identification of Novel Third Generation Synthetic Cannabinoids in Products by Ultra Performance Liquid Chromatography

and Time of Flight Mass Spectrometry”. K. Shanks, T. Dahn, G. Behonick, A. Terrell. J Anal Tox, Manuscript accepted (2013).

“Detection of Synthetic Cannabinoids and Synthetic Stimulants in First and Second Generation Legal Highs by Ultra

Performance Liquid Chromatography with Time of Flight Mass Spectrometry (UPLC/ToF)”. K. Shanks, T. Dahn, G. Behonick, A.

Terrell. J Anal Tox 36: 360-371 (2012)

“Detection of JWH-018 and JWH-073 by UPLC/MS/MS in postmortem whole blood casework”. K. Shanks, T. Dahn, A. Terrell.. J

Anal Tox 36: 145-152 (2012)

Non-Peer Reviewed

“New Drug: metachlorophenylpiperazine (mCPP)”. K. Shanks. ToxTalk. Society of Forensic Toxicologists, Inc. Vol 35, No. 1, p.

21-22.

“New ‘Old’ Drug: Rocuronium (Zemuron)”. K. Shanks. ToxTalk. Society of Forensic Toxicologists, Inc. Vol. 34, No. 2, p. 15-17.

“Evaluation of a LC/MS Method to Screen for Drugs in Postmortem Whole Blood Specimens”. K. Shanks, T. Dahn, A. Terrell, J.

Bohuslavek – Waters Corporation Application Note, 720002113EN, Milford, MA, 2007

Professional Poster Presentations

“Death by ‘Legal Psychedelic Phenethylamines’: Postmortem Tissue Distribution of Desoxypipradrol (2-DPMP) and 4-chloro-

2,5-dimethoxyamphetamine (DOC)”, E.S. Lavins, M. Pietrangelo, K. Shanks, C. Cushman, S. Sofalvi, J. Felo, J.F. Wyman, T.P.

Gilson - American Academy of Forensic Sciences, Washington D.C., 2013

“Methylenedioxypyrovalerone (MDPV) Postmortem Blood Concentrations: A Series of Suicide Case Reports”, G.S. Behonick, K.

Shanks, A.R. Terrell – American Academy of Forensic Sciences, Washington, D.C., 2013

“A Dual Quantitative/Qualitative Screening Analysis for 32 Antidepressants and Metabolites in Human Urine by UPLC/ToF”. K.

Shanks, T. Dahn, A. Terrell – Society of Forensic Toxicologists, Richmond, VA, 2010

“Analysis of Prilocaine in Postmortem Whole Blood and Vitreous Fluid Utilizing UPLC/ToF (Screening) and UPLC/MS/MS

(Confirmation)” M. Klebs, K.Shanks, A. Terrell – Midwest Association of Forensic Science, Des Moines, IA, 2008

“A Rapid, General Unknown Screen in Blood by Ultra Performance Liquid Chromatography and Time of Flight Mass

Spectrometry” K. Shanks, T. Dahn, M. Larson, A. Terrell – American Association of Clinical Chemistry, Washington, D.C., 2008

“Screening of Postmortem Specimens for Drugs of Abuse and Therapeutic Drugs by UPLC/ToF”. K. Shanks, T. Dahn, M. Larson,

A. Terrell, J. Bohuslavek – Society of Forensic Toxicologists, Raleigh-Durham, NC, 2007

“Evaluation of a LC/MS Method to Screen For Drugs in Postmortem Whole Blood Specimens”. K. Shanks, T. Dahn, A. Terrell, J.

Bohuslavek – Society of Forensic Toxicologists, Austin, TX, 2006

Professional Platform and Workshop Presentations

“Designer Drugs: Synthetic Cannabinoids, Stimulants, and Psychedelics”. K. Shanks. American Academy of Family Physicians,

Corporate Health Directors Network, Washington, D.C., 2013

“Cause of Death – Acute Alcohol Poisoning, Manner of Death – Suicide: A Case Study”, G.S. Behonick, K. Shanks, R. Kulhanek,

M.J. Witeck – American Academy of Forensic Sciences, Washington, D.C., 2013

“Scientific Method for Controlled Substance Analog Determination”, L. Reinhold, H.L. Harris, D.E. Forrester, K.P.C. Minbiole, K.

Shanks, J.R. Stenzel, J.G. Rankin – American Academy of Forensic Sciences, Washington, D.C., 2013

“K2, Bath Salts and Emerging Toxicology Trends in the Midwest”, G. Behonick and K. Shanks – Iowa Association of County

Medical Examiners’ Fall Meeting and Education Expo, Des Moines, IA, 2012

“Designing Disaster: The History of the Designer Drug Movement, 1960s to Present”. K. Shanks. Forensic Science Lecture

Series. Indiana Medical History Museum, 2012

“Analytical Challenges of Synthetic Cannabinoids”. K. Shanks. Pharmacology Workshop. Midwest Association of Forensic

Scientists, Milwaukee, WI, 2012

“Drug Facilitated Sexual Assault”. K. Shanks. St. Franciscan Sexual Assault Nurse Examiners (SANE) training. 2012.

“New Designer Drugs – Synthetic Cannabinoids and Synthetic Stimulants”. K. Shanks. Indiana Coroner’s Association, Coroner’s

Conference, Merillville, IN, 2012

“New Designer Drugs – Synthetic Cannabinoids and Synthetic Stimulants”. K. Shanks. Colorado Coroner’s Association,

Coroner’s Conference, Pueblo, CO, 2012

“New Designer Drugs – Synthetic Cannabinoids and Synthetic Stimulants”. K. Shanks. Wyoming Coroner’s Association,

Coroner’s Conference, Sheridan, WY, 2012

“Drug Facilitated Sexual Assault”. K. Shanks. St. Franciscan Sexual Assault Nurse Examiners (SANE) training. 2011.

“New Designer Drugs – Synthetic Cannabinoids and Synthetic Stimulants”. K. Shanks. Kentucky Coroner’s Association, Drug

Death Investigation Course, Lake Barkley, KY, 2011

“General Unknown Screening Using ToF-MS: A Reference Lab Perspective”. K. Shanks. The Association for Mass Spectrometry:

Applications to the Clinical Laboratory, San Diego, CA, 2011

“Nonroutine Case Studies in Forensic Toxicology”. T. Dahn, K. Shanks - Butler University, Indianapolis, IN. Chemistry Seminar,

2010

“UPLC/MS Applications in Forensic Toxicology”. K. Shanks – Midwest Association of Forensic Scientists, Des Moines, IA, 2008

“UPLC and Time of Flight Mass Spectrometry for Unknown Screening in Forensic Toxicology”. K. Shanks – Waters UPLC

Symposium, Indianapolis, IN, 2007

Contact this candidate